Sphera Funds Management Ltd. Ultragenyx Pharmaceutical Inc. Transaction History

Sphera Funds Management Ltd.

$545 Million
Q3 2024

A detailed history of Sphera Funds Management Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 195,349 shares of RARE stock, worth $8.74 Million. This represents 1.99% of its overall portfolio holdings.

Number of Shares

195,349

Previous 293,832 33.52%

Holding current value

$8.74 Million

Previous $12.1 Million 10.14%

% of portfolio

1.99%

Previous 1.77%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $3.96 Million - $5.85 Million	-98,483 Reduced 33.52%	195,349 $10.9 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $2.07 Million - $2.85 Million	55,288 Added 23.18%	293,832 $12.1 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $1.61 Million - $2.01 Million	37,500 Added 18.65%	238,544 $11.1 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $1.84 Million - $2.86 Million	-58,091 Reduced 22.42%	201,044 $9.61 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $2.63 Million - $3.52 Million	75,439 Added 41.07%	259,135 $9.24 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $337,200 - $463,300	10,000 Added 5.76%	183,696 $8.51 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $6.94 Million - $11.5 Million	173,696 New	173,696 $7.19 Million
Q1 2020 May 14, 2020	SELL	$33.8 - $62.9 $3.89 Million - $7.23 Million	-115,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$36.08 - $45.83 $4.15 Million - $5.27 Million	115,000 New	115,000 $4.91 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.

Account

Sphera Funds Management Ltd. Ultragenyx Pharmaceutical Inc. Transaction History